An important question in the pathogenesis and regulation of human gonadotroph adenomas is whether heterogeneous gonadotropin responses to gonadotropin-releasing hormone (GnRH) are due to dysregulation of GnRH receptor biosynthesis and/ or cell-signaling pathways. We investigated gonadotropin responsiveness to pulsatile GnRH in 13 gonadotroph adenomas. All tumors had evidence of follicle-stimulating hormone (FSH) ft and a subunit biosynthesis using reverse transcriptase/polymerase chain reaction (RTPCR) techniques. Four tumors significantly increased gonadotropin and/or free subunit secretion during pulsatile 10-8 M GnRH administration. The GnRH antagonist Antide (10-' to 108 M) blocked secretory increases in all GnRH-responsive tumors. Gonadotropin and/or free subunit secretion increased after 60 mM KCl, confirming that GnRH nonresponsiveness was not due to intracellular gonadotropin depletion. We hypothesized that GnRH nonresponsiveness in these tumors may be due to GnRH receptor (GnRHRc) biosynthetic defects. RTPCR analyses detected GnRH-Rc transcripts only in responsive tumors and normal human pituitary. This is the first demonstration of a cell-surface receptor biosynthetic defect in human pituitary tumors. We conclude (a) one third of gonadotroph tumors respond to pulsatile GnRH in vitro, (b) GnRH-Rc mRNA is detected in human gonadotroph adenomas and predicts GnRH responsiveness, and (c) GnRHRc biosynthetic defects may underlie GnRH nonresponsiveness in gonadotroph tumors. (J. Clin. Invest. 1994.93:2332-2339 
Introduction
The majority of clinically nonfunctioning pituitary adenomas synthesize gonadotropin subunit mRNAs and secrete intact gonadotropins and/or their free subunits ( 1, 2) and are therefore considered to be of a gonadotroph cell origin. There are several lines ofevidence suggesting dysregulation ofgonadotropin and free subunit secretion by gonadotropin-releasing hor-lates gonadotropin secretion in normal individuals (3) . In contrast, < 50% of patients with gonadotropin-secreting tumors exhibit in vivo increases in serum levels of intact gonadotropins and free subunits after an intravenous bolus ofGnRH (4, 5) . Second, desensitization rarely occurs in neoplastic gonadotrophs. Although gonadotropin secretion decreases during continuous GnRH administration in normals, patients with GnRH-responsive pituitary adenomas demonstrate a persistent agonist effect with sustained increases in gonadotropin secretion (5) . GnRH-induced secretory responses have been demonstrated in static cell cultures of pituitary tumors (6) (7) (8) . However, the physiological regulation of neoplastic gonadotrophs by pulsatile GnRH has not been examined in vitro, and little is known about the mechanism underlying GnRH responsiveness in neoplastic gonadotrophs.
Although human pituitary adenomas are clonal in origin, it is unknown how hypothalamic or other factors may potentiate tumor development or lead to specific tumor phenotypes (9, 10) . An important question in the pathogenesis and regulation of human neoplastic gonadotrophs is whether the lack of GnRH responsiveness in a subset oftumors is due to dysregulation of GnRH receptor (GnRH-Rc) biosynthesis and/or cellsignaling pathways. The recent cloning of human receptors for hypothalamic releasing peptides has offered the potential for new insights into receptor expression and function in neoplastic pituitary cells ( 1 1-13) . Data indicate that GnRH-Rc biosynthesis can be regulated by physiological factors such as gonadal steroids as well as homologous regulation by GnRH itself ( 14) . Therefore, the investigation of GnRH-Rc expression is critical for determining both GnRH regulation and potential cell-signaling defects in human tumors of gonadotroph origin. Sequence analysis ofthe human GnRH-Rc has revealed that it is a member ofthe G protein-coupled receptor family ( 13 ). The conserved structure ofthe cloned GnRH-Rc confirms biochemical data that its effects on phospholipases and subsequent phosphatidylinositol hydrolysis is likely mediated by interactions with the Gqa family of GTP-binding proteins ( 15, 16) . Constitutive activation ofthis cell-signaling pathway has mitogenic and transforming effects in NIH3T3 mouse fibroblasts ( 17 ) . Therefore, GnRH-Rc could potentially modulate tumor growth as well as gonadotropin biosynthesis and secretion.
Because of the potential importance of GnRH in pituitary tumor pathogenesis, we investigated (a) intact gonadotropin and free subunit responses to pulsatile physiological GnRH in human gonadotropin-secreting adenomas, (b) blockade with a GnRH antagonist, and (c) whether the presence of GnRH-Rc mRNA predicts GnRH responsiveness in neoplastic gonadotrophs. were obtained in phosphate-buffered saline after transsphenoidal surgery, enzymatically dispersed according to our previously described methods (18) , and incubated overnight in suspension culture containing 10% fetal calf serum/DME (Gibco/BRL, Bethesda, MD). Cells were then pelleted, resuspended in DME/0.1% BSA (Fraction V; Collaborative Research Inc., Lexington, MA), and aliquoted at equal concentrations. Preswollen Bio-Gel P-2 (Bio-Rad Laboratories, Richmond, CA) was used as an attachment matrix for tumor cells. Cells were coincubated with Bio-Gel matrix (500 mg/column; Bio-Rad Laboratories) for 1 h at 37°C in DME/0. 1% BSA, loaded into two columns at equal densities, and perifused at a rate of 200 Ml/min with DME/ 0.1% BSA. Each perifusion column contained an average of 5 X I05 cells. Samples collected during the first 30 min containing unattached red blood cells, cell debris, and gonadotropin stores from lysed cells were discarded. Samples obtained during the next 30 min were used to establish a secretory baseline before pulse administration. Hourly 10-min GnRH pulses (10-8 M) were delivered. Simultaneous antide was administered at variable concentrations, ranging from 10-6 to 10 1o M (19) . In each perifusion experiment, one column received simultaneous antide/GnRH and one control column received GnRH alone.
Methods
To determine tumor intracellular gonadotropin stores, perifusion columns were administered 60 mM KCI for 10 min in isotonic culture media.
RNA extraction and reverse transcriptase/polymerase chain reaction (RTPCR) analysis ofGnRH receptorfrom perifused tumors. Total RNA was successfully extracted after perifusion from 12 of 13 tumors using guanidinium isothiocyanate/phenol/chloroform as described previously (20 RIAs of intact gonadotropins and free subunits. Serum a subunit levels were determined by RIA (22) . The a subunit assay has a detection limit of 0.2 ,g/liter and cross-reactivities of LH, FSH, and thyroid-stimulating hormone (TSH) are 2.7%, 15%, and 10%, respectively. Media a subunit was measured by a monoclonal RIA (Biomerica, Newport Beach, CA) (23). The detection limit for a subunit is 0.05 Mg/liter. Cross-reactivities with each of the intact glycoprotein hormones and free , subunits are < 0.2% and < 0.1%, respectively. Media FSHj3 subunit was measured by RIA (24, 25) . The detection limit of the FSH# assay is 0.2 Mg/liter, and the cross-reactivity of intact FSH is 14%. Cross-reactivities of the assay with each ofthe other intact glycoprotein hormones and free # subunits are < 0.2%. Intact LH and FSH were measured by RIA using polyclonal antibodies specific for the (# subunit, and quantitated using World Health Organization IU Standards IRP 78/ 549 (FSH) and IRP 68/40 (LH). The detection limit of both RIAs is 0.8 IU/liter. Cross reactivities ofthe LH assay are 3.9% for both FSH and TSH, and 1.2% and 1.3% for FSH# and TSHI3, respectively. The cross-reactivities ofthe FSH assay are < 0.03% for all glycoprotein hormones and free subunits.
RIAs ofother pituitary hormones. TSH and prolactin (PRL) hormone concentrations in perifusion media were determined using commercially available double-antibody chemiluminescent assays (Nichols Institute, San Juan Capistrano, CA). Cross-reactivities of each assay with all other pituitary hormones are < 0.1%. Growth hormone (GH) concentrations in perifusion media were determined using a commercially available double-antibody immunoradiometric assay (Nichols Institute). Cross-reactivities of each assay with all other pituitary hormones are < 0.1%. Statistical analysis. Secretory baselines were determined as the mean hormone level released per column fraction during the 20 min preceding each GnRH pulse. Secretory peaks were calculated as maximal hormone released after the GnRH pulse minus the preceding secretory baseline. Secretory responses that were > 2 SDs above preceding baseline were considered significant.
Results
Basal hormone secretion and immunocytochemistry. All 13 tumors secreted one or more intact gonadotropins and/or free subunits during perifusion experiments. Detectable levels of FSH were found in 10 tumors with mean secretory rates ranging from 1.1 to 10.0 IU/liter-min-' (median 2.6 IU/liter min-'). Detectable levels of LH were found in 1 tumors with mean secretory rates ranging from 1.7 to 7.9 IU/liter min-' (median 2.6 IU/liter min'-). Free a and FSH,3 subunit levels were detected in eight and two tumors, respectively. The mean a subunit secretory rate ranged from 0.2 to 0.6 ,gg/liter min-' (median 0.4 ,gg/liter -min-'). The mean FSH# subunit secretory rates were 3.3 and 1.7 ,gg/liter -min-' in tumor 9 and 10, respectively. Immunocytochemical staining was performed on pituitary tumor tissue from each patient using specific antibodies for LH(B, TSHj3, FSH(B, a subunit, GH, PRL, and ACTH (26) . Nine of 13 tumor specimens immunostained positively for one or more gonadotropin subunits. Immunocytochemical staining for GH, PRL, and ACTH was negative in all tumors, and 2 of 13 tumors had rare TSHj3 immunostaining.
To exclude the possibility that normal pituitary tissue contamination was responsible for the observed tumor secretory phenotype in perifusion, medias were assayed for the nongonadotroph hormones, GH, PRL, and TSH (Table II) . Secretion of these nongonadotroph pituitary hormones from perifused gonadotroph tumors was negligible for both GnRH-responsive and -unresponsive tumors. GH was undetectable in all tumors (< 1.0 ,ug/liter). TSH levels were near the detection limit in all tumors, and ranged from 0.06 to 0. 13 mIU/liter (median, 0.07 mIU/liter), whereas PRL levels were also low, ranging from 0.1 to 1.5 ag/liter (median, 0.2 ,ug/liter).
Gonadotropin subunit biosynthesis in perifused tumors. To confirm the gonadotroph origin ofthese tumors, RTPCR analysis was performed for a gonadotropin-specific marker, FSH3, as well as GPH a subunit and GapDH. As shown in Fig. 1 , all 12 perifused tumors showed positive RTPCR amplification for FSHI3 mRNA, as well as GPH a subunit and GapDH. RTPCR reactions with and without reverse transcriptase using RNA from normal human pituitary were included as positive and negative controls, respectively. GnRH responsive tumors. Intact gonadotropins and/or free subunits increased significantly in response to pulsatile GnRH administration in 4 of 13 tumors (tumors 3, 5, 9, and 10). LH was secreted in the perifusion media from all four of the GnRH-responsive tumors. There was a mean increase in LH of 1.5-to 20-fold after GnRH administration. Three of the four responding tumors also secreted FSH (tumors 3, 9, 10), with a mean increase ranging from 1.8-to 5.4-fold after GnRH administration. Pulsatile GnRH also stimulated a-and FSH3-free subunit secretion. The mean increase in a subunit and FSH,3 secretion ranged from 1.2-to 1.8-fold (tumors 3, 9, 10) and from 1.2-to 2-fold (tumors 9 and 10), respectively. GnRH stimulation of FSHJ3 and a subunit was accompanied by stimulation of intact gonadotropin in all cases.
Coordinate secretion of intact FSH andfree FSHJ3 subunit in response to pulsatile GnRH. Two of the four GnRH-responsive tumors secreted both intact FSH and FSHI3 free subunit, whereas FSH,3 was undetectable in all nonresponders. In two responding tumors (tumors 9 and 10), FSH secretory increases were accompanied by increased release of FSH#-free subunit. Coordinate secretion of intact FSH and free FSH# subunit in one tumor (tumor 9) in response to pulsatile GnRH is shown in Fig. 2 pituitary samples. GnRH-unresponsive tumors failed to show amplification of the GnRH-Rc mRNA comparable to levels detected for either responsive tumors or normal pituitary. All tumor mRNA preparations had detectable levels of control GapDH PCR product, and GapDH mRNA from unresponsive tumors amplified with comparable signal intensity as that seen for GnRH-responsive tumors and normal pituitary.
Discussion
We have shown that approximately one third of gonadotroph tumors are responsive to pulsatile GnRH and that GnRH-induced secretory increases can be blocked in a dose-responsive and time-dependent manner by administration of a GnRH antagonist. We report the first identification of human GnRHRc mRNA in neoplastic pituitary tissue using sensitive RTPCR techniques. All GnRH-responsive tumors studied had detectable levels of GnRH-Rc mRNA comparable to those found in normal human pituitary tissue. In contrast, the majority of gonadotroph tumors were unresponsive to pulsatile GnRH in perifusion and did not synthesize detectable levels of GnRH-Rc mRNA. Therefore, the presence of GnRH-Rc mRNA predicts tumor responsiveness to GnRH stimulation in vitro. C f fm f"
tuitary tumors receiving chronic GnRH agonists typically show a persistent agonist effect (5) . These data suggest that gonadotroph tumors may be associated with abnormalities in receptor structure and / or function. It is unknown whether continuous GnRH administration in vitro will lead to desensitization ofgonadotropin secretion in human pituitary tumors. Experiments using normal perifused rat pituitary cells have demonstrated that gonadotropin secretion decreases during continuous GnRH administration for 30-120 min (27) . Recovery of secretory responses is not immediate, and complete recovery can require up to 30 min. Studies investigating gonadotropin responses to continuous GnRH in human gonadotroph tumors in vitro will be necessary to investigate this question. Administration of a GnRH antagonist to normal subjects (28) and normal rat pituitary cells in vitro ( 19) causes a consistent decrease in intact gonadotropin and a subunit secretion without a stimulatory agonist phase. In one study, a 3-12-mo course ofthe Nal-Glu GnRH antagonist to five men with FSHsecreting pituitary tumors significantly decreased serum FSH, LH, and testosterone levels, without affecting adenoma size (29) . In vivo studies are limited by several factors. First, it cannot be determined whether changes in serum hormone levels in treated patients represent tumor versus normal gonadotropin responses. Second, how pulsatile GnRH stimulation controls neoplastic gonadotrophs has not been investigated. Therefore, the physiological regulation of human pituitary tumors by GnRH is unknown. Our present data demonstrate responsiveness to pulsatile GnRH in approximately one third of gonadotroph tumors. We found that all tumors included in this series had evidence of FSHJ3 biosynthesis using RTPCR techniques. Gonadotropin secretion was found in GnRH nonresponsive, as well as GnRH-responsive tumors. The presence of FSH,3 biosynthesis in tumors nonresponsive to GnRH and lacking GnRH-Rc mRNA suggests that FSH3 biosynthesis in these tumors may be regulated by GnRH-independent mechanisms. In all GnRH-responsive tumors, administration ofthe GnRH antagonist Antide blocked gonadotroph secretory responses, consistent with effects seen in normal pituitary tissue. Recovery times of up to 20 min were tested, however, GnRH responsiveness after Antide blockade could not be demonstrated in the tumors studied. These experiments suggest that longer recovery periods are required to reestablish GnRH responsiveness of neoplastic gonadotrophs after Antide blockade.
Altered GnRH pulse characteristics are one mechanism of generating differential gonadotropin subunit gene expression and secretion in normal gonadotrophs. In vitro pituitary perifusion systems have facilitated the precise study of hormone and subunit regulation in response to physiological GnRH in experimental animals (27, (30) (31) (32) (35) .
The lack of detectable GnRH-Rc mRNA in GnRH unresponsive tumors suggests that receptor biosynthesis is deficient in a large subset ofhuman gonadotroph adenomas. Alterations in GnRH-Rc biosynthesis may be the result of cell-signaling defects in neoplastic gonadotrophs. In one model of constitutive activation ofGnRH pathways, continuous in vitro administration of GnRH to normal rat pituitary cells downregulated pituitary GnRH-Rc mRNA levels (14) . This finding suggests that one mechanism of long-term desensitization of GnRH responses by GnRH agonists is to downregulate constitutive GnRH-Rc gene expression and mRNA steady state levels. Therefore, mutations that activate gonadotroph-specific GnRH second messenger pathways could chronically downregulate GnRH-Rc biosynthesis and desensitize neoplastic gonadotrophs to GnRH stimulation. The conserved structure of the cloned GnRH-Rc confirms biochemical data that its effects on phospholipases and subsequent phosphoinositol turnover is likely mediated by interactions with the Gqa family of GTPbinding proteins ( 15, 16) . Constitutive activation of Gqa has mitogenic and transforming effects in NIH3T3 mouse fibroblasts ( 17) . It is unknown whether activating mutations in second messenger systems could potentially have cell proliferative effects as well as desensitizing GnRH-signaling pathways that modulate gonadotropin biosynthesis and secretion.
The gonadotroph origin and phenotype of clinically nonfunctioning pituitary tumors have been described by several groups. We have confirmed the gonadotroph phenotype of these tumors both at the biosynthetic and secretory levels. All 13 tumors secreted LH, FSH, and/or FSHI3 in perifusion. We have previously shown underlying biosynthetic and secretory abnormalities in clinically nonfunctioning pituitary tumors. In contrast to the secretion of both LH and FSH by normal pituitary tissue, preferential secretion of FSH and FSH3-free subunit is seen in a subset of tumors (34) . We have confirmed these findings in this group of tumors by performing RTPCR for FSH,3 mRNA. All 13 tumors synthesized FSH/3 mRNA in addition to GPH a subunit and GapDH, consistent with their gonadotroph phenotype in perifusion. Several lines ofevidence suggest that normal tissue contamination is not a complicating factor in this study. First, the 13 perifused gonadotroph tumors in this study do not exhibit significant in vitro secretion ofGH, PRL, and TSH, an expected result if perifused gonadotroph tumors were composed of large numbers of normal pituitary cells. Second, we might also expect a histological description of normal tissue in resected tumor samples, however, all tissue received was histologically diagnosed as adenoma tissue. Third, human pituitary tumors have been demonstrated to be genetically monoclonal in origin (9, (36) (37) (38) (39) (40) . Because contamination of normal pituitary tissue would give a polyclonal result, the consistent finding of monoclonality in both macro-and microadenomas argue strongly against normal tissue contamination in our samples. Fourth, our finding that one third of human gonadotroph adenomas are responsive to GnRH in vitro is in agreement with previous studies documenting both secretory (6, 7) and intracellular (8) responses to GnRH in static culture. These complementary approaches strongly suggest that normal pituitary tissue contamination of resected human gonadotroph tumors is not a factor in our analysis.
In contrast to the uniform LH and FSH responses to physiological GnRH in normal pituitary cells, only one third of pituitary tumors are GnRH responsive in vitro. We have demonstrated the presence ofGnRH-Rc in human pituitary gonadotropin-secreting adenomas. GnRH-Rc transcripts were detected only in responsive tumors, and the levels were comparable to those seen in normal human pituitaries. Therefore, GnRH-Rc mRNA steady state levels in such tumors predict GnRH responsiveness in vitro. These studies suggest that GnRH nonresponsiveness in gonadotroph tumors may be due to GnRH-Rc biosynthetic defects. In addition, the documentation ofFSH3 biosynthesis in tumors lacking GnRH-Rc mRNA and responsiveness to exogenous GnRH suggests the importance of GnRH-independent mechanisms in the regulation of gonadotropin biosynthesis in a subset oftumors. Future investigations will need to characterize such defects and determine their role in tumor pathogenesis.
